XOMA Corporation (XOMA) Analysts See $-0.23 EPS on May, 8

April 17, 2018 - By Sheila Anderson

XOMA Corporation (NASDAQ:XOMA) Corporate Logo

Investors wait XOMA Corporation (NASDAQ:XOMA)’s quarterly earnings on May, 8., Zacks reports. Analysts forecast $-0.23 EPS. That’s $2.07 up or 90.00 % from 2017’s earnings of $-2.3. 43.75 % negative EPS growth is what analysts predict. $-0.16 EPS was revealed for last [previous quarter]. The stock increased 0.68% or $0.15 during the last trading session, reaching $22.08.XOMA Corporation has volume of 83,387 shares. Since April 17, 2017 XOMA has risen 184.45% and is uptrending. The stock outperformed the S&P500 by 172.90%.

XOMA Corporation (NASDAQ:XOMA) Ratings Coverage

Total analysts of 3 have positions in XOMA (NASDAQ:XOMA) as follows: 2 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 67%. Since October 17, 2017 according to StockzIntelligence Inc XOMA has 9 analyst reports. The stock rating was maintained by H.C. Wainwright with “Buy” on Thursday, January 18. On Tuesday, November 14 H.C. Wainwright maintained the shares of XOMA in report with “Buy” rating. On Friday, March 9 the firm has “Buy” rating given by H.C. Wainwright. On Tuesday, October 17 the firm has “Buy” rating given by H.C. Wainwright. The stock rating was maintained by H.C. Wainwright with “Buy” on Tuesday, November 7. On Thursday, December 7 H.C. Wainwright maintained the shares of XOMA in report with “Buy” rating. The company rating was maintained by Wedbush on Tuesday, December 19. On Tuesday, February 6 the stock of XOMA Corporation (NASDAQ:XOMA) earned “Buy” rating by Wedbush.

XOMA Corporation discovers, develops, and commercializes antibody therapeutics in the United States, Europe, and the Asia Pacific.The firm is valued at $183.97 million. The company's product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia.30.33 is the P/E ratio. The Company’s preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy.

XOMA Corporation (NASDAQ:XOMA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.